Arcutis Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $39.75, Implies 17% Upside
Arcutis Biotherapeutics, Inc. saw its average price target raised by analysts from $39.12 to $39.75, with a range of $34 to $48. This implies a 17% upside from the Nov. 4 closing price. The consensus rating remains 'Buy' among 8 analysts, with 7 Buys, 1 Hold, and 0 Sells.
How this was made

The 30-second read
Why it matters
Analyst consensus remains a Buy, with 7 Buys and 1 Hold, indicating continued confidence.
Market read
The price‑target increase may attract short‑term buying interest but is unlikely to cause a large move.
What to watch
Potential regulatory or clinical trial setbacks that are not reflected in the new target.
Background
Arcutis Biotherapeutics is a clinical-stage biotech focused on dermatology and immunology.
Market effects
May lift sentiment in the biotech sector as analysts show confidence in Arcutis.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact; primarily relevant to investors tracking small-cap biotech stocks.
Counterpoint
The target raise could be premature if upcoming trial data disappoints.
Key entities
- companyArcutis Biotherapeutics, Inc.
Clinical-stage biotech company.
